Stockholm - Free Realtime Quote SEK

Orexo AB (publ) (ORX.ST)

19.44

+0.06

+(0.31%)

As of 10:56:24 AM GMT+1. Market Open.

Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis

Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces positive topline results from the clinical study OX640-002. The study evaluated the performance in subjects with and without allergic rhinitis when treated with Orexo´s nasal rescue medication including powder-based epinephrine, OX640.

PR Newswire 3 days ago

ORXOF

ORXOY
Abera and Orexo partner for vaccine powder formulations

The main funding source for the partnership is the Coalition for Epidemic Preparedness Innovations.

Pharmaceutical Technology 26 days ago

ORXOY
Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology

Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), continues to develop its innovative powder-based drug delivery technology AmorphOX to improve the properties of new or existing drugs. The aim is to develop formulations that help to significantly stabilize the active ingredient and enable alternative and more effective routes of administration. AmorphOX-based formulations can be used for a wide range of active ingredients, from small molecules and peptides to larger biomolecules such as vaccines.

PR Newswire 28 days ago

ORXOF

ORXOY
Orexo initiates new study of OX640 in participants with allergic rhinitis

Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces the first participants have been dosed with OX640, an intranasal rescue medication for severe allergic reactions (incl. anaphylaxis) with powder-based epinephrine, in a new study in subjects with allergic rhinitis (hay fever). The study will be completed during 2024 with results available early in 2025.

PR Newswire 2 months ago

ORXOF

ORXOY
Orexo AB (ORXOY) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic Growth ...

Despite revenue declines and regulatory hurdles, Orexo AB (ORXOY) focuses on strategic partnerships and product development to drive future growth.

GuruFocus.com 2 months ago

ORXOY
Orexo Interim Report Q3 2024

Q3 2024 highlights

PR Newswire 2 months ago

ORXOF

ORXOY
Orexo´s Nomination Committee for the Annual General Meeting 2025

The members of the Nomination Committee for the Annual General Meeting (AGM), that takes place on May 8, 2025, have been appointed and comprises of the following members:

PR Newswire 3 months ago

ORXOF

ORXOY
Orexo to participate in Pareto Securities´ 15th Annual Healthcare Conference 2024

Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY), today announces the company will participate in Pareto Securities' 15th Annual Healthcare Conference, that takes place on September 19, at Downtown Camper by Scandic, Brunkebergstorg 9, Stockholm, Sweden.

PR Newswire 4 months ago

ORXOF

ORXOY
FDA issues CRL to Orexo’s NDA for opioid overdose medication

The US regulator has sought an additional human factors study, consistent with prior communications.

Pharmaceutical Technology 5 months ago

ORXOY
Orexo Q2 2024 Interim Report

Making progress, while the OX124 review time extended

PR Newswire 5 months ago

ORXOF

ORXOY
Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose

Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that the company has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for OX124, a high-dose naloxone rescue medication in development for opioid overdose. The NDA was submitted to the FDA on September 18, 2023. The CRL indicates the need for an additional Human Factors (HF) study, which is in line with previous communication. Furthermore, additional techn

PR Newswire 5 months ago

ORXOF

ORXOY
OTC Markets Hosts Virtual Investor Presentation with Nikolaj Sorensen, President and CEO of Orexo AB, and Brad Sorensen, Senior Analyst at Zacks SCR

OTCQX:ORXOY | STO:ORX John Viglotti: Hello and welcome to Virtual Investor Conferences. My name is John Viglotti, and on behalf of OTC Markets, as well as our co-host Zacks Small Cap Research, we're very pleased you joined us for our next presentation from Orexo. Their session will be moderated by Brad Sorensen. He's a senior equity research analyst with Zacks Small Cap Research. Please note, you

Zacks Small Cap Research 6 months ago

ORXOF

ORXOY
Orexo AB´s sustainability work ranked among top 5% by EcoVadis

Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) announces that it has received a Gold Sustainability Rating by EcoVadis, one of the world´s most trusted provider of business sustainability ratings. The highly revered award places the company in the top 5 percent of all 70,000 businesses worldwide that are reviewed by EcoVadis each year.

PR Newswire 6 months ago

ORXOF

ORXOY
Orexo: invitation to presentation of the Q2 2024 Interim Report

As previously communicated Orexo will announce the Interim Report for the second quarter of 2024 on July 17 at 8 am CET. The same day at 2 pm, analysts, investors, and media are invited to attend a presentation where Nikolaj Sørensen, CEO, and Fredrik Järrsten, CFO, will present the latest development and host a Q&A.

PR Newswire 6 months ago

ORXOF

ORXOY
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, June 21, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum held June 20th are now available for online viewing. REGISTER NOW AT: https://bit.ly/4cbVF5U The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download in

GlobeNewswire 6 months ago

LGVN

LGVNR

GLABF
Life Sciences Virtual Investor Forum Agenda Announced for June 20th

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, June 18, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Virtual Investor Forum to be held on June 20th, 2024. This event is co-sponsored by Zack’s Small Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER NOW AT: https://bit.ly/4bUev

GlobeNewswire 6 months ago

GLABF

BBLG

BBLGW
Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm

On March 28, 2024, Orexo AB (publ), ("Orexo" or the "Company") (STO: ORX) (OTCQX: ORXOY) successfully issued senior secured callable floating rate social bonds in an amount of SEK 500 million and with a tenor of four years (the "Bonds").

PR Newswire 8 months ago

ORXOF

ORXOY
Orexo Q1 2024 Interim Report

Starting 2024 with a positive EBITDA

PR Newswire 8 months ago

ORXOF

ORXOY
Report from Orexo AB's annual general meeting, 26 April 2024

Election of the board of directors and auditor

PR Newswire 8 months ago

ORXOF

ORXOY
Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US

Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that the United States Patent and Trademark Office (USPTO) has granted another US patent specifically related to OX640, Orexo's nasal epinephrine powder product based on the AmorphOX® drug delivery platform.

PR Newswire 8 months ago

ORXOF

ORXOY

Performance Overview

Return	ORX.ST	OMX Stockholm 30 Index
YTD	+11.09%	+1.73%
1-Year	+31.35%	+7.22%
3-Year	-41.69%	+5.34%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Orexo AB (publ) (ORX.ST)

Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis

Abera and Orexo partner for vaccine powder formulations

Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology

Orexo initiates new study of OX640 in participants with allergic rhinitis

Orexo AB (ORXOY) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic Growth ...

Orexo Interim Report Q3 2024

Orexo´s Nomination Committee for the Annual General Meeting 2025

Orexo to participate in Pareto Securities´ 15th Annual Healthcare Conference 2024

FDA issues CRL to Orexo’s NDA for opioid overdose medication

Orexo Q2 2024 Interim Report

Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose

OTC Markets Hosts Virtual Investor Presentation with Nikolaj Sorensen, President and CEO of Orexo AB, and Brad Sorensen, Senior Analyst at Zacks SCR

Orexo AB´s sustainability work ranked among top 5% by EcoVadis

Orexo: invitation to presentation of the Q2 2024 Interim Report

Life Science Virtual Investor Forum Presentations Now Available for Online Viewing

Life Sciences Virtual Investor Forum Agenda Announced for June 20th

Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm

Orexo Q1 2024 Interim Report

Report from Orexo AB's annual general meeting, 26 April 2024

Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US

Performance Overview